Literature DB >> 27013388

Re-exploration of the mGlu₁ PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR.

Pedro M Garcia-Barrantes1, Hyekyung P Cho2, Tahj M Starr1, Anna L Blobaum1, Colleen M Niswender3, P Jeffrey Conn3, Craig W Lindsley4.   

Abstract

This letter describes the re-exploration of the mGlu1 PAM Ro 07-11401 scaffold through a multi-dimensional, iterative parallel synthesis approach. Unlike recent series of mGlu1 PAMs with robust SAR, the SAR around the Ro 07-11401 structure was incredibly steep (only ∼6 of 200 analogs displayed mGlu1 PAM activity), and reminiscent of the CPPHA mGlu5 PAM scaffold. Despite the steep SAR, two new thiazole derivatives were discovered with improved in vitro DMPK profiles and ∼3- to 4-fold improvement in CNS exposure (Kps 1.01-1.19); albeit, with a ∼3-fold diminution in mGlu1 PAM potency, yet comparable efficacy (∼5-fold leftward shift of the glutamate concentration-response curve at 10μM). Thus, this effort has provided additional CNS penetrant mGlu1 PAM tools in a different chemotype than the VU0486321 scaffold. These compounds will permit a better understanding of the pharmacology and therapeutic potential of selective mGlu1 activation, while highlighting the steep SAR challenges that can often be encountered in GPCR allosteric modulator discovery.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Metabotropic glutamate receptor; Positive allosteric modulator (PAM); Schizophrenia; Structure–Activity Relationship (SAR); mGlu(1)

Mesh:

Substances:

Year:  2016        PMID: 27013388      PMCID: PMC4833523          DOI: 10.1016/j.bmcl.2016.03.044

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  20 in total

1.  Protective role for type-1 metabotropic glutamate receptors against spike and wave discharges in the WAG/Rij rat model of absence epilepsy.

Authors:  R T Ngomba; I Santolini; F Biagioni; G Molinaro; A Simonyi; C M van Rijn; V D'Amore; F Mastroiacovo; G Olivieri; R Gradini; F Ferraguti; G Battaglia; V Bruno; A Puliti; G van Luijtelaar; F Nicoletti
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

2.  Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA.

Authors:  Zhijian Zhao; David D Wisnoski; Julie A O'Brien; Wei Lemaire; David L Williams; Marlene A Jacobson; Marion Wittman; Sookhee N Ha; Herve Schaffhauser; Cyrille Sur; Doug J Pettibone; Mark E Duggan; P Jeffrey Conn; George D Hartman; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2006-12-03       Impact factor: 2.823

Review 3.  Recent advances in the medicinal chemistry of the metabotropic glutamate receptor 1 (mGlu₁).

Authors:  Dafydd R Owen
Journal:  ACS Chem Neurosci       Date:  2011-03-10       Impact factor: 4.418

4.  Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 1: SAR of modifications to the central aryl core.

Authors:  Pedro M Garcia-Barrantes; Hyekyung P Cho; Anna L Blobaum; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2015-10-09       Impact factor: 2.823

5.  A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between the rat and human receptors.

Authors:  Hyekyung P Cho; Darren W Engers; Daryl F Venable; Colleen M Niswender; Craig W Lindsley; P Jeffrey Conn; Kyle A Emmitte; Alice L Rodriguez
Journal:  ACS Chem Neurosci       Date:  2014-05-15       Impact factor: 4.418

Review 6.  "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology.

Authors:  Michael R Wood; Corey R Hopkins; John T Brogan; P Jeffrey Conn; Craig W Lindsley
Journal:  Biochemistry       Date:  2011-03-04       Impact factor: 3.162

7.  9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers.

Authors:  Eric Vieira; Jörg Huwyler; Synèse Jolidon; Frédéric Knoflach; Vincent Mutel; Jürgen Wichmann
Journal:  Bioorg Med Chem Lett       Date:  2005-10-15       Impact factor: 2.823

8.  Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool.

Authors:  Pedro M Garcia-Barrantes; Hyekyung P Cho; Adam M Metts; Anna L Blobaum; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2016-01-02       Impact factor: 2.823

9.  Deleterious GRM1 mutations in schizophrenia.

Authors:  Mohammed Akli Ayoub; Dora Angelicheva; David Vile; David Chandler; Bharti Morar; Juleen A Cavanaugh; Peter M Visscher; Assen Jablensky; Kevin D G Pfleger; Luba Kalaydjieva
Journal:  PLoS One       Date:  2012-03-20       Impact factor: 3.240

10.  Clustered coding variants in the glutamate receptor complexes of individuals with schizophrenia and bipolar disorder.

Authors:  René A W Frank; Allan F McRae; Andrew J Pocklington; Louie N van de Lagemaat; Pau Navarro; Mike D R Croning; Noboru H Komiyama; Sophie J Bradley; R A John Challiss; J Douglas Armstrong; Robert D Finn; Mary P Malloy; Alan W MacLean; Sarah E Harris; John M Starr; Sanjeev S Bhaskar; Eleanor K Howard; Sarah E Hunt; Alison J Coffey; Venkatesh Ranganath; Panos Deloukas; Jane Rogers; Walter J Muir; Ian J Deary; Douglas H Blackwood; Peter M Visscher; Seth G N Grant
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

View more
  5 in total

1.  Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators.

Authors:  Samantha E Yohn; Daniel J Foster; Dan P Covey; Mark S Moehle; Jordan Galbraith; Pedro M Garcia-Barrantes; Hyekyung P Cho; Michael Bubser; Anna L Blobaum; Max E Joffe; Joseph F Cheer; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  Mol Psychiatry       Date:  2018-08-16       Impact factor: 15.992

Review 2.  Shared Behavioral and Neurocircuitry Disruptions in Drug Addiction, Obesity, and Binge Eating Disorder: Focus on Group I mGluRs in the Mesolimbic Dopamine Pathway.

Authors:  Samantha E Yohn; Jordan Galbraith; Erin S Calipari; P Jeffrey Conn
Journal:  ACS Chem Neurosci       Date:  2019-04-15       Impact factor: 4.418

Review 3.  Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.

Authors:  James Maksymetz; Sean P Moran; P Jeffrey Conn
Journal:  Mol Brain       Date:  2017-04-26       Impact factor: 4.041

Review 4.  Allosteric Molecular Switches in Metabotropic Glutamate Receptors.

Authors:  Zoltán Orgován; György G Ferenczy; György M Keserű
Journal:  ChemMedChem       Date:  2020-08-25       Impact factor: 3.466

Review 5.  Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease.

Authors:  Deborah J Luessen; P Jeffrey Conn
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.